US Stock MarketDetailed Quotes

Inhibikase Therapeutics (IKT)

Watchlist
  • 1.700
  • +0.020+1.19%
Close Jan 14 16:00 ET
206.15MMarket Cap3.62P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Inhibikase Therapeutics (IKT) Revenue Breakdown Overview

By Business/Source

Currency:USD
2023/FY
Stock NameRevenueRatio
Developing protein kinase inhibitor therapeutics260.5K100.00%

By Country/Region

Currency:USD
2023/FY
Stock NameRevenueRatio
United States260.5K100.00%
Market Insights
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +3.17%
Sample Name
Sample Code
 +1.87%
Sample Name
Sample Code
 +1.81%
4
AT&T
T
+1.33%
5
Interactive Brokers
IBKR
+1.08%
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +23.99%
Sample Name
Sample Code
 +22.01%
Sample Name
Sample Code
 +15.78%
4
GDS Holdings
GDS
+14.31%
5
ASE Technology
ASX
+7.15%
View More
The Fed Delivers Third Consecutive Rate Cut as Expected! How to Position for Year-End U.S. Equity Ma
On December 19, the Bank of Japan raised interest rates by 25 basis points as expected, in line with market forecasts. On the evening of Dec Show More
December FOMC Interest Rate Meeting
[Opportunity Express] MRVL Continues to Bet on Optical Interconnects: Is Now a Good Time to Enter the Market?

- No more -